Artificial pancreas devices so far cannot compensate the daily varying food intake or physical activities of diabetes patients. The University of Bern, the Bern University Hospital and an industry partner have therefore set out to develop a more flexible device to continuously control patients’ blood sugar.
"Today, a diabetic patient must follow a very constraining therapy with many blood glucose measurements, dose calculations and insulin injections. The ideal would be to have a single system that can conduct all of these operations without requiring any intervention", says Prof. Peter Diem, Chairman and Head of the Department of Endocrinology, Diabetes and Clinical Nutrition at Inselspital.
Such a system needs to continuously measure and calculate the level of glucose present in the blood and to constantly deliver insulin via an infusion pump. The amount of infused insulin is determined by an algorithm that estimates the patient needs based on the measured glucose levels, the time of day or the expected activities and that will adapt the pump infusion rate accordingly.
Insulin need depends on daily activity and food profile
"Approaches taken so far do not resolve fundamental difficulties: the patients' variability, uncertainties related to system disturbances, e.g. food intake and physical activity, and errors related to the used devices,” says Dr. Stavroula Mougiakakou, Head of the Diabetes Technology Research Group at the University of Bern’s ARTORG Center.
“The proposed algorithm is easy to use, introduces the concept of real-time personalisation based on reinforcement learning, is able to tackle inter- and intra-patient variability, and can compensate for the effects of uncertain events."
Artificial pancreas has to work accurately and flexibly
The new artificial pancreas ARTORG and Inselspital wish to develop will include an infusion pump produced by an industry partner and an algorithm to run on a wireless PDA device used for the programming of the pump. The accuracy of the different elements in an artificial pancreas is critical.
The insulin levels have to be maintained in a very narrow window. Too little insulin will lead to hyperglycaemia, while too much insulin generates hypoglycaemia. Both situations may induce coma and even patient death. The proposed pump therefore emphasizes on accuracy and flexibility.
The patch pump will be directly placed on the skin, to continuously monitor therapy. It can be detached and reattached at will. A prototype of the pump has been tested by patients in a first clinical trial. After development and integration, the new control algorithm for the personalised delivery of insulin will be verified in a number of clinical trials.
"We are looking forward to seeing this new approach being used by patients and appreciate how much this may facilitate their treatment. It is even more important to improve their quality of life", says Prof. Christoph Stettler, newly elected Director of the Division of Endocrinology, Diabetes and Clinical Nutrition at Inselspital.
On diabetes therapy:
Prof. Dr.med. Peter Diem, Chairman and Head, Division of Endocrinology, Diabetes and Clinical Nutrition, Inselspital, Bern University Hospital, +41 31 632 4070, email@example.com.
On the algorithm:
PD Dr. Stavroula Mougiakakou, ARTORG Center - Diabetes Technology Research, +41 31 632 75 92, firstname.lastname@example.org.
On the infusion pump:
Laurent-Dominique Piveteau, Press Contacts, Debiotech SA, +41 21 623 60 00, email@example.com.
Monika Kugemann | Universitätsspital Bern
Collagen nanofibrils in mammalian tissues get stronger with exercise
14.12.2018 | University of Illinois College of Engineering
New discoveries predict ability to forecast dementia from single molecule
12.12.2018 | UT Southwestern Medical Center
The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.
Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
14.12.2018 | Power and Electrical Engineering
14.12.2018 | Physics and Astronomy
14.12.2018 | Physics and Astronomy